INTRODUCTION {#sec1}
============

*Saccharomyces cerevisiae* is used on a massive scale for industrial production of ethanol from cane sugar and hydrolysed corn starch, in which fermentable sugars predominantly occur as hexoses or hexose dimers (Renewable Fuel Association [@bib2]). In contrast, hydrolysis of lignocellulosic feedstocks such as the agricultural residues corn stover, corn cobs and wheat straw, yields mixtures of pentose and hexose sugars (Lynd [@bib29]; van Maris *et al.*[@bib53]). Industrial ethanol production from lignocellulosic feedstocks therefore requires efficient conversion of pentose and hexose sugars into ethanol (Lynd [@bib29]). In most lignocellulosic hydrolysates, [d]{.smallcaps}-xylose represents up to 25% of the total sugar monomers while another pentose, [l]{.smallcaps}-arabinose, typically accounts for up to 3% of the sugar content. In some industrially relevant hydrolysates, such as those derived from corn-fibre hydrolysates and sugar-beet pulp, [l]{.smallcaps}-arabinose can account for up to 26% of the sugar content (Grohmann and Bothast [@bib16]; Grohmann and Bothast [@bib17]; van Maris *et al.*[@bib53]).

Since wild-type *S. cerevisiae* strains cannot ferment pentoses, metabolic engineering is required to enable utilization of these substrates. Strategies to engineer *S. cerevisiae* for [d]{.smallcaps}-xylose fermentation are either based on heterologous expression of a fungal [d]{.smallcaps}-xylose reductase and xylitol dehydrogenase or on expression of a heterologous [d]{.smallcaps}-xylose isomerase (Jeffries [@bib20]; Kuyper *et al.*[@bib26]; Kuyper *et al.*[@bib25]). Current [l]{.smallcaps}-arabinose-fermenting *S. cerevisiae* strains are based on functional expression of genes encoding [l]{.smallcaps}-arabinose isomerase (AraA), [l]{.smallcaps}-ribulokinase (AraB) and [l]{.smallcaps}-ribulose-5-phosphate-4-epimerase (AraD) from bacteria such as *Escherichia coli*, *Bacillus subtilis* or *Lactobacillus plantarum* (Sedlak and Ho [@bib40]; Becker and Boles [@bib4]; Wisselink *et al.*[@bib66]). Unlike the fungal [l]{.smallcaps}-arabinose pathway (Richard *et al.*[@bib38]), the bacterial pathway enables conversion of [l]{.smallcaps}-arabinose to [d]{.smallcaps}-xylulose-5-phosphate via redox-cofactor-independent reactions (Becker and Boles [@bib4]; Wisselink *et al.*[@bib66]). As previously shown for engineered [d]{.smallcaps}-xylose-consuming strains (Kuyper *et al.*[@bib25]), overexpression of the *S. cerevisiae* genes encoding xylulokinase (Xks1, EC 2.7.1.17), ribulose 5-phosphate epimerase (Rpe1, EC 5.3.1.1), ribulose 5-phosphate isomerase (Rki1, EC 5.3.1.6), transketolase (Tkl1, EC 2.2.1.1) and transaldolase (Tal1, EC 2.2.1.2) enabled efficient coupling of the heterologously expressed [l]{.smallcaps}-arabinose pathway to glycolysis and alcoholic fermentation (Wisselink *et al.*[@bib66]). Subsequent laboratory evolution yielded an efficient [l]{.smallcaps}-arabinose fermenting strain, which combined a high ethanol yield (0.43 g g^−1^) with an ethanol production rate of 0.29 g h^−1^ \[g biomass\] ^−1^ and an arabinose consumption rate of 0.70 g h^−1^ \[g biomass\]^−1^) (Wisselink *et al.*[@bib66]). Transcriptome studies identified that increased expression of the genes encoding 'secondary' isoenzymes of transaldolase (*NQM1*) and transketolase (*TKL2*) contributed to improved [l]{.smallcaps}-arabinose fermentation of this laboratory-evolved strain (Wisselink *et al.*[@bib67]). Improvements in [l]{.smallcaps}-arabinose fermentation were also achieved by codon optimization of bacterial [l]{.smallcaps}-arabinose genes to match the codon preference of highly expressed glycolytic yeast genes (Wiedemann and Boles [@bib63]).

Transport of pentose sugars in *S. cerevisiae* occurs by facilitated diffusion, mediated by native HXT hexose transporters (Hamacher *et al.*[@bib19]; Becker and Boles [@bib4]). Transport of [l]{.smallcaps}-arabinose predominantly occurs via the hexose transporter Gal2 which, however, exhibits a much lower affinity for [l]{.smallcaps}-arabinose than for [d]{.smallcaps}-glucose or galactose (Kou, Christensen and Cirillo [@bib23]; Becker and Boles [@bib4]; Subtil and Boles [@bib43]; Subtil and Boles [@bib44]). Of the other *S. cerevisiae* HXT transporters, only Hxt9p and Hxt10p show low rates of [l]{.smallcaps}-arabinose transport (Subtil and Boles [@bib43]). In practice, expression of *GAL2* has been found to be essential for [l]{.smallcaps}-arabinose fermentation by strains that do not express heterologous transporters (Becker and Boles [@bib4]; Wisselink *et al.*[@bib67]; Subtil and Boles [@bib43]; Wang *et al.*[@bib61]). Recently, an *in silico* model of the three-dimensional structure of Gal2, based on the crystal structure of the *E. coli* xylose permease XylEp, was used to predict mutations in *GAL2* that improve [l]{.smallcaps}-arabinose docking in Gal2. Based on this theoretical analysis, single-amino-acid substitutions were introduced at position 85 of Gal2 and shown to significantly increase [l]{.smallcaps}-arabinose transport activity (Wang *et al.*[@bib61]).

Since transcription of *GAL2* is both induced by [d]{.smallcaps}-galactose and repressed by [d]{.smallcaps}-glucose, design of [l]{.smallcaps}-arabinose-fermenting *S. cerevisiae* strains often includes expression of *GAL2* behind a strong constitutive promoter (Tani *et al.*[@bib46]; Wang *et al.*[@bib61]). Alternatively, laboratory evolution can result in upregulation of *GAL2* (Wisselink *et al.*[@bib64]; Wisselink *et al.*[@bib67]). However, [l]{.smallcaps}-arabinose transport by Gal2 is also subject to strong competitive inhibition by [d]{.smallcaps}-glucose (Subtil and Boles [@bib44]; Knoshaug *et al.*[@bib22]), which precludes simultaneous utilization of [l]{.smallcaps}-arabinose and [d]{.smallcaps}-glucose in batch cultures grown on sugar mixtures (Wisselink *et al.*[@bib64]; Wisselink *et al.*[@bib67]).

To improve the kinetics of [l]{.smallcaps}-arabinose transport, transporter genes from other yeasts, filamentous fungi and plants have been functionally expressed in [l]{.smallcaps}-arabinose-metabolizing *S. cerevisiae* strains (Subtil and Boles [@bib43]; Verho, Penttilä and Richard [@bib56]; Knoshaug *et al.*[@bib22]; Li *et al.*[@bib28]; Bracher *et al.*[@bib7]). K~m~ values of these heterologous transporters for [l]{.smallcaps}-arabinose ranged from 0.13 to 263 mM, while reported V~max~ values ranged from 0.4 to 171 \[nmol [l]{.smallcaps}-arabinose (mg biomass)^−1^ min^−1^\]. Several heterologous transporters, including the high-affinity [l]{.smallcaps}-arabinose proton symporter *Pc*AraT from *P. chrysogenum* (Bracher *et al.*[@bib7]) allowed for [l]{.smallcaps}-arabinose uptake in the presence of [d]{.smallcaps}-glucose (Subtil and Boles [@bib43]; Knoshaug *et al.*[@bib22]; Li *et al.*[@bib28]; Bracher *et al.*[@bib7]).

Laboratory evolution of pentose-fermenting *S. cerevisiae* strains in which [d]{.smallcaps}-glucose phosphorylation was abolished has been successfully used to select strains in which [l]{.smallcaps}-arabinose or [d]{.smallcaps}-xylose uptake is less sensitive to [d]{.smallcaps}-glucose inhibition (Farwick *et al.*[@bib14]; Nijland *et al.*[@bib33]; Wisselink *et al.*[@bib65]). Single-amino-acid substitutions, found at corresponding positions in the hexose transporters Hxt7 (N370) and Gal2 (N376), as well as in a chimera of Hxt3 and Hxt6 (N367), were shown to substantially decrease inhibition of [d]{.smallcaps}-xylose transport by [d]{.smallcaps}-glucose (Farwick *et al.*[@bib14]; Nijland *et al.*[@bib33]).

The aim of the present study was to identify mutations that enable anaerobic growth of engineered, [l]{.smallcaps}-arabinose-fermenting *S. cerevisiae* strains on [l]{.smallcaps}-arabinose in the presence of [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose, with a focus on mutations that affect uptake of [l]{.smallcaps}-arabinose. To this end, we constructed a glucose-phosphorylation-negative, [l]{.smallcaps}-arabinose-fermenting *S. cerevisiae* strain by Cas9-assisted genome editing. This strain was then subjected to prolonged laboratory evolution in sequential batch bioreactor cultures, grown on mixtures of [l]{.smallcaps}-arabinose, [d]{.smallcaps}-xylose and [d]{.smallcaps}-glucose. Subsequently, causal mutations for glucose-insensitive growth on [l]{.smallcaps}-arabinose were identified by whole-genome sequencing and functional analysis of mutant alleles in non-evolved strain backgrounds.

MATERIALS AND METHODS {#sec2}
=====================

Strains and maintenance {#sec2-1}
-----------------------

The *S. cerevisiae* strains used and constructed in this study (Table [1](#tbl1){ref-type="table"}) were derived from the CEN.PK lineage (Entian and Kötter [@bib13]; Nijkamp *et al.*[@bib31]). All stock cultures were grown in shake flasks on synthetic medium (SM, see below) or, in case of auxotrophic strains, on yeast-extract/peptone (YP) medium (10 g L^−1^ Bacto yeast extract (Becton Dickinson, Franklin Lakes, NJ) and 20 g L^−1^ Bacto Peptone (Becton Dickinson)) (Verduyn *et al.*[@bib55]). These media were either supplemented with 20 g L^−1^[d]{.smallcaps}-glucose or, in case of the constructed glucose-phosphorylation-negative strains, 20 g L^−1^[l]{.smallcaps}-arabinose. For storage and in pre-cultures, single-colony isolates obtained after laboratory evolution were grown in medium containing 20 g L^−1^ of each [d]{.smallcaps}-glucose, [d]{.smallcaps}-xylose and [l]{.smallcaps}-arabinose. After adding glycerol (30% vol/vol) to these cultures, 1 mL aliquots were stored at −80°C.

###### 

*Saccharomyces cerevisiae* strains used in this study.

  Strain                     Relevant genotype                                                                                                                                                                                                                                                        Reference
  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------
  CEN.PK 113--7D             *MATa MAL2--8c SUC2*                                                                                                                                                                                                                                                     Nijkamp *et al.*[@bib32]
  IMX080                     *MATa ura3--52 his3--1 leu2--3112 MAL2--8c SUC2 glk1::Sphis5, hxk1::KlLEU2*                                                                                                                                                                                              Solis-Escalante *et al.*[@bib41]
  IMX486                     *MATa ura3--52 his3--1 leu2--3112 MAL2--8c SUC2 glk1::Sphis5, hxk1::KlLEU2 gal1::cas9-amdS*                                                                                                                                                                              This study
  IMX604                     *MATa ura3--52 his3--1 leu2--3112 MAL2--8c SUC2 glk1::Sphis5, hxk1::KlLEU2 gal1::cas9- amdS gre3::pTDH3_RPE1 pPGK1_TKL1, pTEF1_TAL1 pPGI1_NQM1 pTPI1_RKI1 pPYK1_TKL2*                                                                                                    This study
  IMX658                     *MATa ura3--52 his3--1 leu2--3112 MAL2--8c SUC2 glk1::Sphis5, hxk1::KlLEU2 gal1::cas9- amdS gre3::pTDH3_RPE1 pPGK1_TKL1, pTEF1_TAL1 pPGI1_NQM1 pTPI1_RKI1 pPYK1_TKL2 gal80::(pTPI_araA_tCYC)\*9 pPYK-araB-tPGI1 pPGK-araD-tTDH3*                                         This study
  IMX660                     *MATa ura3--52 his3--1 leu2--3112 MAL2--8c SUC2 glk1::Sphis5, hxk1::KlLEU2 gal1::cas9- amdS gre3::pTDH3_RPE1 pPGK1_TKL1, pTEF1_TAL1 pPGI1_NQM1 pTPI1_RKI1 pPYK1_TKL2 gal80::(pTPI_araA_tCYC)\*9 pPYK-araB-tPGI1 pPGK-araD-tTDH3 hxk2*::*KlURA3*                          This study
  IMX728                     *MATa ura3--52 his3--1 leu2--3112 MAL2--8c SUC2 glk1::Sphis5, hxk1::KlLEU2 gal1::cas9- amdS gre3::pTDH3_RPE1 pPGK1_TKL1, pTEF1_TAL1 pPGI1_NQM1 pTPI1_RKI1 pPYK1_TKL2 gal80::(pTPI_araA_tCYC)\*9 pPYK-araB-tPGI1 pPGK-araD-tTDH3 hxk2:: PcaraT*                           This study
  IMX1106                    *MATa ura3--52 his3--1 leu2--3112 MAL2--8c SUC2 glk1::Sphis5, hxk1::KlLEU2 gal1::cas9- amdS gre3::pTDH3_RPE1 pPGK1_TKL1, pTEF1_TAL1 pPGI1_NQM1 pTPI1_RKI1 pPYK1_TKL2 gal80::(pTPI_araA_tCYC)\*9 pPYK-araB-tPGI1 pPGK-araD-tTDH3 hxk2*::*KlURA3 gal2::gal2^N376I^*        This study
  IMX1386                    *MATa ura3--52 his3--1 leu2--3112 MAL2--8c SUC2 glk1::Sphis5, hxk1::KlLEU2 gal1::cas9- amdS gre3::pTDH3_RPE1 pPGK1_TKL1, pTEF1_TAL1 pPGI1_NQM1 pTPI1_RKI1 pPYK1_TKL2 gal80::(pTPI_araA_tCYC)\*9 pPYK-araB-tPGI1 pPGK-araD-tTDH3 hxk2*::*KlURA3 CAN1::pGAL2_GAL2_tGAL2*   This study
  IMS0514                    IMX728 that has undergone laboratory evolution on a mixture of arabinose and glucose under aerobic conditions                                                                                                                                                            This study
  IMS0520                    IMX728 that has undergone laboratory evolution on mixture of arabinose, glucose and xylose under anaerobic conditions                                                                                                                                                    This study
  IMS0521                    IMX728 that has undergone laboratory evolution on mixture of arabinose, glucose and xylose under anaerobic conditions                                                                                                                                                    This study
  IMS0522                    IMX728 that has undergone laboratory evolution on mixture of arabinose, glucose and xylose under anaerobic conditions                                                                                                                                                    This study
  IMS0523                    IMX728 that has undergone laboratory evolution on mixture of arabinose, glucose and xylose under anaerobic conditions                                                                                                                                                    This study
  IMW088                     *As IMS0522; PcAraTΔ*                                                                                                                                                                                                                                                    This study
  IMW091                     *As IMS0522; gal2^I89T^*                                                                                                                                                                                                                                                 This study
  DS68616                    *Mat a, ura3--52, leu2--112, gre3::loxP, loxP-Ptpi:TAL1, loxP-Ptpi::RKI1, loxP-Ptpi-TKL1, loxP-Ptpi-RPE1, delta::Padh1XKS1Tcyc1-LEU2, delta::URA3-Ptpi-xylA-Tcyc1*                                                                                                       DSM, The Netherlands
  DS68625                    DS68616, *his3::loxP, hxt2::loxP-kanMX-loxP, hxt367::loxP-hphMX-loxP, hxt145::loxP-natMX-loxP, gal2::loxP-zeoMX-loxP*                                                                                                                                                    Nijland *et al.*[@bib33]
  DS68625-Gal2               DS68616, *his3::loxP, hxt2::loxP-kanMX-loxP, hxt367::loxP-hphMX-loxP, hxt145::loxP-natMX-loxP, gal2::loxP-zeoMX-loxP*                                                                                                                                                    This study
  DS68625-Gal2^N376I^        DS68616, *his3::loxP, hxt2::loxP-kanMX-loxP, hxt367::loxP-hphMX-loxP, hxt145::loxP-natMX-loxP, gal2::loxP-zeoMX-loxP*                                                                                                                                                    This study
  DS68625-Gal2^N376S^        DS68616, *his3::loxP, hxt2::loxP-kanMX-loxP, hxt367::loxP-hphMX-loxP, hxt145::loxP-natMX-loxP, gal2::loxP-zeoMX-loxP*                                                                                                                                                    This study
  DS68625-Gal2^N376T^        DS68616, *his3::loxP, hxt2::loxP-kanMX-loxP, hxt367::loxP-hphMX-loxP, hxt145::loxP-natMX-loxP, gal2::loxP-zeoMX-loxP*                                                                                                                                                    This study
  DS68625-Gal2^N376T/T89I^   DS68616, *his3::loxP, hxt2::loxP-kanMX-loxP, hxt367::loxP-hphMX-loxP, hxt145::loxP-natMX-loxP, gal2::loxP-zeoMX-loxP*                                                                                                                                                    This study
  DS68625-Gal2^T89I^         DS68616, *his3::loxP, hxt2::loxP-kanMX-loxP, hxt367::loxP-hphMX-loxP, hxt145::loxP-natMX-loxP, gal2::loxP-zeoMX-loxP*                                                                                                                                                    This study
  DS68625-mcs                DS68616, *his3::loxP, hxt2::loxP-kanMX-loxP, hxt367::loxP-hphMX-loxP, hxt145::loxP-natMX-loxP, gal2::loxP-zeoMX-loxP*                                                                                                                                                    This study

Cultivation and media {#sec2-2}
---------------------

All strain characterization studies were performed in SM prepared as described previously (Verduyn *et al.*[@bib55]). Carbon source and vitamin solutions were added after autoclaving the medium for 20 min at 121 °C. Concentrated solutions (50% w/w) of [d]{.smallcaps}-glucose, [d]{.smallcaps}-xylose and [l]{.smallcaps}-arabinose were autoclaved separately at 110 °C for 20 min. Prior to inoculation 20 g L^−1^[l]{.smallcaps}-arabinose (SMA), 20 g L^−1^[d]{.smallcaps}-glucose (SMG), 20 g L^−1^[l]{.smallcaps}-arabinose and 20 g L^−1^[d]{.smallcaps}-glucose (SMAG) or 20 g L^−1^[l]{.smallcaps}-arabinose, 20 g L^−1^[d]{.smallcaps}-glucose and 20 g L^−1^[d]{.smallcaps}-xylose (SMAGX) were added to SM as carbon sources. Aerobic shake-flask cultures were grown in an orbital shaker at 200 rpm set at 30 °C, using 500-ml flasks containing 100 ml medium. For plates 20 g L^−1^ agar (BD) was added prior to autoclaving at 121 °C for 20 min. Aerobic shake-flask cultures used as pre-cultures for anaerobic cultures were inoculated with frozen stocks and, in late-exponential phase, a 1 mL sample was used to start a second aerobic pre-culture. Anaerobic batch cultures used for characterization were inoculated from these cultures to obtain an initial OD~660~ of 0.5. Anaerobic shake-flask cultures were incubated at 30°C in an Innova anaerobic chamber (5% H~2~, 6% CO~2~ and 89% N~2~, New Brunswick Scientific, Edison, NJ) in 50 mL shake flasks placed on an orbital shaker set at 200 rpm. Bioreactor batch cultures were performed at 30°C in 2-L laboratory bioreactors (Applikon, Delft, The Netherlands) with a working volume of 1 L. Culture pH was controlled at 5.0 by automatic addition of 2 M KOH and cultures were stirred at 800 rpm. Anaerobic bioreactors were equipped with Viton O-rings and Norprene tubing (Cole Palmer Instrument Company, Vernon Hills, IL) to minimize oxygen diffusion and continuously sparged with nitrogen gas (\< 10 ppm oxygen) at 0.5 L min^−1^. After autoclaving, synthetic media were supplemented with 0.2 g L^−1^ antifoam C (Sigma-Aldrich, St. Louis, MO). Furthermore, the anaerobic growth factors Tween 80 (420 mg L^−1^) and ergosterol (10 mg L^−1^) were added to the medium as described previously (Verduyn *et al.*[@bib54]). Laboratory evolution experiments were performed in sequential batch reactors (SBRs). On-line measurement of CO~2~ concentrations in the off gas of SBRs was used as input for a control routine programmed in MFCS/win 3.0 (Sartorius AG, Göttingen, Germany). An empty-refill cycle was automatically initiated when the CO~2~ concentration in the off gas had first exceeded a threshold value of 0.2% and subsequently declined below 0.1% as fermentable sugars were depleted. After the emptying phase, when approximately 7% of the initial culture volume was left in the reactor, the reactor was automatically refilled with fresh medium from a 20-L reservoir, which was continuously sparged with nitrogen gas. After ca. 450 generations of selective growth, single colony isolates were obtained by plating culture samples on SMAGX agar, supplemented with Tween 80 (420 mg L^−1^) and ergosterol (10 mg L^−1^). Plates were incubated in an anaerobic chamber for 6 d and restreaked three times to obtain single-cell lines.

Plasmid and strain construction {#sec2-3}
-------------------------------

The plasmids constructed and used in this study are shown in Additional File 1. The open reading frames of *araA* \[Genbank: ODO63149.1, encoding [l]{.smallcaps}-arabinose isomerase\], *araB* \[Genbank: ODO63147.1, encoding [l]{.smallcaps}-ribulose kinase\] and *araD* \[Genbank: ODO63147.1, encoding [l]{.smallcaps}-ribulose-5-phosphate epimerase\] were codon optimized based on the codon usage in glycolytic genes in *S. cerevisiae* (Wiedemann and Boles [@bib63]), synthesized behind the promoter of *TPI1*, *PGK1* and *PYK1* originating from CEN.PK113--7D and cloned in pMK-RQ based vectors by GenArt GmbH (Regensburg, Germany). These plasmids were named pUD354-pUD356 and transformed into *E. coli* DH5a cells. Plasmid DNA was isolated from *E. coli* cultures using a GenElute Plasmid kit (Sigma-Aldrich, St. Louis, MO). PCR amplification of expression cassettes and plasmid fragments was performed using Phusion High Fidelity DNA Polymerase (Thermo Scientific, Waltham, MA). *S. cerevisiae* strains were transformed as described by Gietz and Woods (Gietz *et al.*[@bib15]). To facilitate CRISPR/Cas9-mediated genome editing in strain *S. cerevisiae* IMX080, a Cas9 expression cassette PCR-amplified from p414-TEF1p-cas9-CYCt using primers 4653--5981 as well as a second fragment containing the amdSYM marker cassette, PCR amplified from pUG-amdSYM with primers 3093--1678 (Solis-Escalante *et al.*[@bib42]), were *in vivo* co-assembled and integrated (Kuijpers *et al.*[@bib24]) into the *GAL1* locus through a double cross over mediated by homologous recombination (Additional File 3a). After each transformation round, the cells were restreaked thrice and correct integration of all the fragments was confirmed by diagnostic PCR. Transformants were selected on solid SM with acetamide (Solis-Escalante *et al.*[@bib42]) as sole nitrogen source and checked by diagnostic PCR using DreamTaq polymerase (Thermo Scientific), according to the manufacturer\'s protocol. The resulting strain IMX486 was subsequently transformed with 200 pmol each of eight DNA fragments containing expression cassettes for the genes encoding the enzymes of the non-oxidative branch of the pentose phosphate pathway, which were PCR amplified from pUD344--346 and two 500bp fragments containing flanking regions of *GRE3* amplified from CEN.PK113--7D genomic DNA, using oligonucleotide primers shown in Additional File 2. These fragments were co-transformed with 500 ng of plasmid pUDE335 to induce a double strand break in the *GRE3* locus using CRISPR-Cas9 (Additional File 3b). The cells were plated on SMD plates and correct assembly of all six fragments in the *GRE3* locus was verified by diagnostic colony PCR. Plasmid pUDE335 was counter selected on YP with 20 g L^−1^[d]{.smallcaps}-glucose (YPD) agar with 5-fluoroorotic acid (5-FOA) as described previously (Mans *et al.*[@bib30]). The resulting strain IMX604 was then transformed with nine DNA fragments that carried expression cassettes for *araA* and single fragments for *araB* and *araD* amplified from pUD354--356. The primers used for PCR amplification of these fragments added homologous regions required for *in-vivo* assembly and integration into the *GAL80* locus (Additional File 3c). The fragments were co-transformed with gRNA-plasmid pUDE348, which was constructed as described previously (Verhoeven *et al.*[@bib57]). After verification of the correct assembly and integration of the fragments by diagnostic PCR, plasmid pUDE348 was counter selected with 5-FOA, yielding strain IMX658. *HXK2* was deleted by inducing a double strand break using the gRNA plasmid pUDE327, and using an expression cassette for the *PcaraT* gene, obtained by PCR amplification from plasmid Pwt118, as the repair fragment (Additional File 3d). After counter selection of pUDE327 with 5-FOA, a DNA fragment carrying the *URA3* gene from CEN.PK113--7D was amplified using primers 2641--1522 and transformed to restore a wild-type *URA3* gene, yielding strain IMX728. Strain IMX660 was constructed from IMX658 by transforming a *KlURA3* based knock-out cassette targeting the *HXK2* locus.

Strain IMX1386 was obtained by co-transforming IMX728 with plasmid pROS13 and a fragment containing the promoter region, ORF and terminator of *GAL2*, PCR amplified from genomic DNA of strain CEN.PK113--7D with primer pair 7285--7286. Transformants were selected on YP with 20 g L^−1^[l]{.smallcaps}-arabinose (YPA) supplemented with G418. After verifying correct integration of the *GAL2* expression cassette in the *CAN1* locus, the gRNA plasmid was counter selected by serial plating on YPA as described previously (Mans *et al.*[@bib30]). The gRNA plasmids pUDR172 and pUDR187 were constructed using pROS13 as template by Gibson assembly according to the method described by Mans *et al.* (Mans *et al.*[@bib30]). The single nucleotide polymorphism (SNP) at position 1127 in *GAL2* was inserted by co-transforming strain IMX660 with pUDR172 and a repair fragment containing the single nucleotide change resulting in the amino acid substitution from N to I at position 376. Expression cassettes of the *GAL2*, *GAL2*^N376I^ and *GAL2*^N376S^ variants were amplified using genomic DNA from CEN.PK113--7D, IMS0520 and IMS0514 as template using the primers F_Gal2_XbaI and R_Gal2_Cfr9I (Supplemental Table S2) and subsequently cloned into plasmid pRS313-P7T7. To obtain the *GAL2*^N376T^, *GAL2*^N376T/T89I^ and *GAL2*^T89I^ mutants, fragments were PCR amplified from CEN.PK113--7D genomic DNA using the primers shown in Supplemental Table S2. Subsequently, overlap PCR amplifications were done to obtain the full-length genes encoding for Gal2^N376T^, Gal2^N376T/T89I^ and Gal2^T89I^. All genes were cloned into pRS313-P7T7 and subsequently confirmed by Sanger sequencing (Baseclear).

The Gal2 variants and the pRS313-P7T7-mcs plasmid (as an empty plasmid/control) were transformed to the hexose transporter deletion strain DS68625 and positive colonies were named DS68625-Gal2, DS68625-Gal2 N376I, DS68625-Gal2 N376S, DS68625-Gal2 N376T, DS68625-Gal2 N376T/T89I, DS68625-Gal2 T89I and DS68625-mcs. To revert the altered amino acid position 89 in Gal2 from isoleucine to threonine, pUDR187 and a repair fragment containing the original coding sequence were co-transformed. Inactivation of *Pc*AraT in IMS0522 was achieved by *in-vivo* assembling of the pROS13 backbone and the gRNA expression cassette, both PCR amplified from pROS13 using the primers shown in Additional File 2 and providing a repair oligo for *HXK2*. After verifying correct transformants the plasmids were removed by counter selection on YPAGX plates and the resulting strains were named IMW091 and IMW088, respectively.

Analytical methods {#sec2-4}
------------------

To monitor growth of batch cultures, a Libra S11 spectrometer (Biochrom, Cambridge, United Kingdom) was used for optical density measurements at 660 nm. To calculate specific growth rates, biomass dry weight measurements were performed on at least six samples taken during the exponential growth phase. Dry weight measurements were performed by filtering 10 mL culture samples over pre-weighed nitrocellulose filter (pore size, 0.45 μm; Gelman Laboratory, Ann Arbor, MI). The filter was washed with demineralized water and dried in a microwave oven (Bosch, Stuttgart, Germany) for 20 min at 360 W. The correlation between these CDW measurements and the corresponding OD data was used to estimate CDW in samples for which no direct CDW measurements were done. Metabolite concentrations in culture supernatants, obtained by centrifugation, were determined by high-performance liquid chromatography (HPLC) on an Agilent 1260 HPLC (Agilent Technologies, Santa Clara, CA) equipped with a Bio-Rad HPX 87 H column (Bio-Rad, Hercules, CA). The column was eluted at 60 °C with 0.5 g L^−1^ H~2~SO~4~ at a flow rate of 0.6 ml min^−1^. Detection was by means of an Agilent G1362A refractive-index detector and an Agilent G1314F VWD detector. CO~2~ and O~2~ concentrations were measured in bioreactor off gas using an NGA 2000 analyzer (Rosemount Analytical, Orrville, OH) after it was first cooled by a condenser (2 °C) and dried with a Permapure MD-110--48P-4 dryer (Permapure, Toms River, NJ). Correction for ethanol evaporation was done for all bioreactor experiments as described previously (Guadalupe Medina *et al.*[@bib18]).

DNA sequence analysis {#sec2-5}
---------------------

Genomic DNA for sequencing was isolated using the QIAGEN Blood & Cell Culture Kit With 100/G Genomic-tips (QIAGEN, Valencia, CA) according to the manufacturer\'s protocol. DNA libraries were prepared using the Nextera XT DNA library Preparation Kit (Illumina, San Diego, CA), yielding 300bp fragments. The Libraries were sequenced using the Illumina MiSeq platform (Illumina, San Diego, CA, USA). Data were aligned and mapped to the CEN.PK113--7D genome using the Burrows--Wheeler alignment tool (Li and Durbin [@bib27]). Variant calling by Pilon (Walker *et al.*[@bib58]) was checked with the Integrated Genomics Viewer (Thorvaldsdóttir, Robinson and Mesirov [@bib47]). The Poisson mixture model based algorithm Magnolya (Nijkamp *et al.*[@bib31]) was used to detect and quantify chromosomal copy number variations (CNV). Copy numbers of *AraA, AraB, AraD* and *Pc*AraT were estimated as described previously using the average read depth of the chromosomes that did not contain any duplication according to the CNV analysis done with Magnolya (Verhoeven *et al.*[@bib57]). Genome sequence data of strains IMS0520, IMS0521, IMS0522, IMS0523, IMS514 and parental strains IMX728 and IMX660 have been deposited at the NCBI Sequence Read archive ([www.ncbi.nlm.nih.gov/sra](http://www.ncbi.nlm.nih.gov/sra)) with the corresponding BioProject ID PRJNA414371. *GAL2* ORFs from strains IMS0002 and IMS0010 and the nucleotides surrounding position T89 in IMS0003 and IMS0007 were PCR amplified from genomic DNA using primers as listed in Additional File 2 and sanger sequenced (Baseclear).

Sugar transport assays {#sec2-6}
----------------------

Strains expressing *GAL2* alleles in the DS68625 strain background were pre-grown in aerobic shake flasks on SM with 20 g L^−1^[d]{.smallcaps}-xylose, after which cells were collected by centrifugation (3000 g, 3 min), washed and re-suspended in SM without sugar. Uptake experiments were initiated by adding \[^14^C\] [l]{.smallcaps}-arabinose or \[^14^C\] [d]{.smallcaps}-glucose (ARC St. Louis, MO, USA) to the cell suspension at concentrations ranging from 0.2 to 500 mM. \[^14^C\] [l]{.smallcaps}-arabinose and \[^14^C\] [d]{.smallcaps}-glucose (50--60 mCi mmol^−1^) were added at concentrations of 0.1 mCi ml^−1^. At set time points, uptake was arrested by adding 5 mL of ice-cold 0.1 M LiCl, filtration over 0.45-μm HV membrane filters (Millipore, France) and washing with 5 mL ice-cold 0.1 M LiCl. Radioactivity on the filters was then counted using a Liquid Scintillation Counter (PerkinElmer, Waltham, MA) in Ultima Gold MV Scintillation cocktail (PerkinElmer). [d]{.smallcaps}-Glucose inhibition experiments were measured using 50 mM \[^14^C\] [l]{.smallcaps}-arabinose with \[^14^C\] [d]{.smallcaps}-glucose added at concentrations between 50 and 500 mM.

RESULTS {#sec3}
=======

Construction of a *S. cerevisiae*[l]{.smallcaps}-arabinose specialist strain {#sec3-1}
----------------------------------------------------------------------------

To investigate uptake and growth on [l]{.smallcaps}-arabinose in the presence of [d]{.smallcaps}-glucose, an [l]{.smallcaps}-arabinose 'specialist strain' was constructed by Cas9-assisted genome editing. First, a Cas9 expression cassette (DiCarlo *et al.*[@bib11]) and the counter-selectable marker cassette amdSYM (Solis-Escalante *et al.*[@bib42]) were *in vivo* assembled and integrated at the *GAL1* locus in *S. cerevisiae* IMX080 (*hxk1Δ glk1Δ*) (Additional File 3a). In the resulting strain IMX486 (*hxk1Δ glk1Δ gal1Δ::*{*Spcas9*-amdSYM}, *HXK2* was the sole remaining functional hexose kinase. Subsequently, cassettes for constitutive expression of *RPE1, RKI1, TKL1, TKL2, TAL1* and *NQM1*, which encode (iso)enzymes of the non-oxidative pentose-phosphate pathway (NPPP), were *in vivo* assembled and integrated at the *GRE3* locus of strain IMX486, yielding strain IMX658 (*hxk1Δ glk1Δ gal1Δ::*{*Spcas9*-amdSYM} *gre3Δ::*{NPPP}) (Additional File 3b). Inactivation of *GRE3* prevents xylitol formation by the Gre3 non-specific aldose reductase (Träff *et al.*[@bib49]; Kuyper *et al.*[@bib25]). To introduce a functional bacterial [l]{.smallcaps}-arabinose pathway (ARAP) (Wisselink *et al.*[@bib66]), the *Lactobacillus plantarum* genes encoding [l]{.smallcaps}-arabinose isomerase (AraA), ribulokinase (AraB) and ribulose-5P epimerase (AraD) were codon optimized and placed under the control of the strong constitutive promoters of *TPI1*, *PGI1* and *TDH3*, respectively. For high expression of *AraA*, we used the multi-copy tandem integration strategy previously described for high-level expression of xylose isomerase which, in laboratory evolution experiments, facilitates rapid adaptation of copy number by homologous recombination (Verhoeven *et al.*[@bib57]). Using this approach, nine copies of the *AraA* cassette and single copies of the *AraB* and *AraD* cassettes were integrated at the *GAL80* locus by *in vivo* assembly and Cas9-mediated integration (Additional File 3c). Inactivation of *GAL80* eliminates the need for galactose induction of *GAL2* expression (Torchia *et al.*[@bib48]; Ostergaard *et al.*[@bib34]; Tani *et al.*[@bib46]). Expression of the high-affinity [l]{.smallcaps}-arabinose transporter *Pc*AraT from *P. chrysogenum* enables [l]{.smallcaps}-arabinose uptake in the presence of glucose (Bracher *et al.*[@bib7]). To simultaneously abolish the ability to metabolize [d]{.smallcaps}-glucose, an expression cassette for *Pc*AraT (Bracher *et al.*[@bib7]) was integrated into the *HXK2* locus. Subsequent introduction of a functional *URA3* allele from *S. cerevisiae* CEN.PK113--7D (Additional File 3d) yielded the prototrophic 'arabinose specialist' *S. cerevisiae* strain IMX728 (*hxk1Δ glk1Δ gal1Δ::*{*Spcas9*-amdSYM} *gre3Δ::*{NPPP} *hxk2Δ::PcaraT gal80Δ*::{ARAP}).

In aerobic shake flasks on SMA, strain IMX728 exhibited a specific growth rate of 0.26 h^−1^ (Fig. [1](#fig1){ref-type="fig"}). As anticipated after deletion of all four genes encoding glucose-phosphorylating enzymes (Farwick *et al.*[@bib14]; Nijland *et al.*[@bib33]; Wisselink *et al.*[@bib65]), no growth was observed on SMG~~D~~. Consistent with the incomplete inhibition of *Pc*AraT by glucose (Bracher *et al.*[@bib7]), strain IMX728 grew at a specific growth rate of 0.04 h^−1^ in aerobic batch cultures on SMAGX (Fig. [1](#fig1){ref-type="fig"}).

![Growth curves of *S. cerevisiae* strain IMX728 (engineered, non-evolved arabinose-consuming, glucose-phosphorylation-negative, expressing *PcaraT*) in aerobic batch cultures on SM containing 20 g L^−1^[l-]{.smallcaps}arabinose (SMA) as sole carbon and energy source (~•~) and in SM with 20 g L^−1^[l-]{.smallcaps}arabinose, 20 g L^−1^[d]{.smallcaps}-glucose and 20 g L^−1^[d]{.smallcaps}-xylose added ($\documentclass[12pt]{minimal}
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}{}$\circ$\end{document}$). Data shown in the figure represent from a single growth experiment, data from a replicate experiment are shown in Additional File 4. Derived biomass-specific conversion rates in the replicate experiments differed by less than 5%.](foy062fig1){#fig1}

Anaerobic laboratory evolution of an engineered [l]{.smallcaps}-arabinose specialist in the presence of [d]{.smallcaps}-glucose {#sec3-2}
-------------------------------------------------------------------------------------------------------------------------------

The ability of strain IMX728 to grow anaerobically on [l]{.smallcaps}-arabinose as sole carbon source was investigated in anaerobic bioreactors. In contrast to the fast and instantaneous growth in aerobic shake flasks (Fig. [1](#fig1){ref-type="fig"}), slow anaerobic growth on [l]{.smallcaps}-arabinose was observed only after approximately 150 h (Additional File 5). To select for spontaneous mutants that combined an increased anaerobic growth rate on [l]{.smallcaps}-arabinose with a decreased sensitivity to growth inhibition by [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose, strain IMX728 was grown in duplicate anaerobic SBRs on SMAGX. Continuous measurements of CO~2~ concentrations in the off gas of the SBRs were used to automatically initiate empty-refill cycles and monitor the increase of specific growth rate over time (Additional File 6). After an initial cultivation cycle under aerobic conditions, the first anaerobic cycle required a 17d period before growth was observed. Only then, within 24 h, both replicate cultures showed an exponential increase in CO~2~ production, corresponding to an estimated specific growth rate of 0.07 h^−1^. Both SBRs were operated for 254 d (Fig. [2](#fig2){ref-type="fig"}), after which specific growth rates had increased to above 0.13 h^−1^. Specific growth rates on SMAGX of 31 single-colony isolates obtained from the SBR cultures were then measured in anaerobic shake flasks (Additional File 7). Four selected isolates, named IMS0520 to IMS0523, showed specific growth rates of 0.13 to 0.17 h^−1^ in anaerobic bioreactor batch cultures on SMAGX, which corresponded closely to the growth rates estimated from on-line CO~2~ analysis of the evolving SBR cultures (Additional File 8).

![Specific growth rate (h^−1^) estimated from CO~2~ production profiles in two parallel laboratory evolution experiments in anaerobic SBRs SBR 1 ($\documentclass[12pt]{minimal}
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}{}$\circ$\end{document}$) and SBR 2 (~•~). Both cultures were inoculated with the [l]{.smallcaps}-arabinose consuming, glucose-phosphorylation-negative *S. cerevisiae* strain IMX728 and grown on SM with 20 g L^−1^[l]{.smallcaps}-arabinose, 20 g L^−1^[d]{.smallcaps}-glucose and 20 g L^−1^[d]{.smallcaps}-xylose. The first data point for each experiment corresponds to the initial aerobic batch cultivation, all subsequent data points represent estimated growth rates in anaerobic SBR cycles.](foy062fig2){#fig2}

Evolved strains show mutations, duplication and allelic variation in *GAL2* {#sec3-3}
---------------------------------------------------------------------------

To identify the mutations that enabled growth of laboratory-evolved isolates IMS0520-IMS0523 on [l]{.smallcaps}-arabinose in the presence of [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose, their genomes were sequenced and compared to that of their common parental strain IMX728. Variant screening for non-synonymous single-nucleotide mutants and insertion/deletions revealed that, together, the four strains carried 9 single-nucleotide mutations in open reading frames (Table [2](#tbl2){ref-type="table"}). All four isolates carried mutations in *GAL2* that changed the asparagine in position 376 of Gal2, into an isoleucine (Gal2^N376I^) or a threonine (Gal2^N376T^) in isolates originating from SBR 1 and 2, respectively. Isolate IMS0522 contained an additional single-nucleotide mutation in *GAL2* resulting in a Gal2^T89I^ substitution, which, however, was observed only in 57% of the reads already suggesting a copy number increase of *GAL2* locus.

###### 

Single-nucleotide mutations in [l]{.smallcaps}-arabinose-metabolizing, glucose-phosphorylation-negative *S. cerevisiae* strains IMS0520-IMS0523, evolved for anaerobic growth on [l]{.smallcaps}-arabinose in the presence of [d]{.smallcaps}-xylose and [d]{.smallcaps}-glucose in biological duplicate (reactors 1 and 2). Mutants were identified alignment of the whole-genome sequence data to *S. cerevisiae* IMX728. Read coverage observed for each SNP was higher than 99% unless stated otherwise in the table. Descriptions of gene functions are derived from the *Saccharomyces* Genome Database (as of 19--11-2017).

  Gene and strain       Nucleotide change   Amino acid change   Description
  --------------------- ------------------- ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *GAL2*                                                        Galactose permease; required for utilization of galactose and also able to transport glucose (Kou, Christensen and Cirillo [@bib23])
  IMS0520 (reactor 1)   A1127T              N376I               
  IMS0521 (reactor 1)   A1127T              N376I               
  IMS0522 (reactor 2)   A1127C              N376T               
  IMS0523 (reactor 2)   C266T (57%)         T89I                
                        A1127C              N376T               
  *BMH1*                                                        14--3-3 protein, major isoform; controls, involved in regulation of exocytosis, vesicle transport, Ras/MAPK and rapamycin-sensitive signalling, aggresome formation, spindle position checkpoint
  IMS0520 (reactor 1)   G383T               G128V               
  IMS0522 (reactor 2)   G64T                E22\*               
  IMS0523 (reactor 2)   G64T                E22\*               
  *DCK1*                                                        Dock family protein (Dedicator Of CytoKinesis), homolog of human DOCK1; interacts with Ino4p; cytoplasmic protein that relocates to mitochondria under oxidative stress
  IMS0522 (reactor 2)   T2890C (42%)        Y964H               
  *IPT1*                                                        Inositolphosphotransferase; involved in synthesis of mannose-(inositol-P)2-ceramide (M(IP)2C) sphingolipid; can mutate to resistance to the antifungals syringomycin E and DmAMP1 and to *K. lactis* zymocin
  IMS0522 (reactor 2)   C938T               S313F               
  *UPC2*                                                        Sterol regulatory element binding protein; induces sterol biosynthetic genes, upon sterol depletion; acts as a sterol sensor, binding ergosterol in sterol rich conditions;
  IMS0523(reactor 2)    A2648G              Y883C               
  *RPL6B*                                                       Ribosomal 60S subunit protein L6B; binds 5.8S rRNA; homologous to mammalian ribosomal protein L6,
  IMS0520 (reactor 1)   T784A               E261G               

In addition to mutations in *GAL2*, single-nucleotide changes were identified in *DCK1*, *IPT1 UPC2* and *RPL6B*, which each occurred in only one of the four isolates. *IPT1* encodes an inositol phosphotransferase involved in sphingolipid production (Dickson *et al.*[@bib12]), while *UPC2* plays a key role in regulation of sterol metabolism and uptake (Crowley *et al.*[@bib9]). Both mutations may have affected membrane composition and, thereby, the uptake of [l]{.smallcaps}-arabinose. Mutations in *BMH1* were observed in strains IMS0520, IMS0522 and IMS0523. In view of the pleiotropic phenotype of *bmh1* mutants (van Heusden *et al.*[@bib52]; Roberts, Mösch and Fink [@bib39]; Van Hemert, van Heusden and Steensma [@bib51]; Wang *et al.*[@bib59]), we decided to not investigate the impact of these mutations on [l]{.smallcaps}-arabinose fermentation. Since, *GAL2* was the only transporter gene whose coding region was found to be mutated in strain IMS0521, further analysis was focused on the *GAL2* mutations found in the four strains.

As frequently observed in laboratory evolution experiments with *S. cerevisiae* (Oud *et al.*[@bib35]; de Vries, Pronk and Daran [@bib10]), read depth analysis revealed changes in copy number of specific regions in the genomes of the evolved strains (Additional File 9). Notably, regions of Chromosome XII, which harbors *GAL2*, were found to be duplicated in all four isolates, with strain IMS0522 showing a probable duplication of this entire chromosome (Fig. [3](#fig3){ref-type="fig"}). To test the physiological significance of the resulting duplication of *GAL2*, an additional copy of the wild-type *GAL2* allele was integrated in the genome of the parental 'arabinose specialist' IMX728, yielding strain IMX1386. Similar to *S. cerevisiae* IMX728, the strain with two copies of *GAL2* required 120h before growth on [l]{.smallcaps}-arabinose was observed in anaerobic batch cultures (Additional File 10), indicating that duplication of *GAL2* was not, in itself, sufficient to enable instantaneous anaerobic growth on [l]{.smallcaps}-arabinose.

![Chromosomal copy number estimations for chromosome 12 in the evolved anaerobically [l-]{.smallcaps}arabinose-growing, glucose-tolerant *S. cerevisiae* strains IMS0520 to IMS0523. Chromosomal copy numbers were estimated using the Magnolya algorithm (Nijkamp *et al.*[@bib31]). Reads of the four strains (red crosses) show duplications relative to the corresponding chromosome 12 sequences in the common parental strain IMX728 (blue crosses). The light blue region corresponds to the location of *GAL2*.](foy062fig3){#fig3}

Read-depth comparisons of the genes encoding the enzymes of the bacterial [l]{.smallcaps}-arabinose pathway (araA, araB, araD) revealed some differences in copy number of *araA* and *araB* between evolved strains and the parental strain (Table [3](#tbl3){ref-type="table"}). However, these differences were not consistent across the four evolved strains. Read-depth analysis of the *PcaraT* transporter gene revealed no copy number changes in any of the four evolved isolates. To examine the contribution of *PcaraT* to the physiology of the evolved strains, it was deleted in evolved strain IMS0522, resulting in strain IMW088. In duplicate anaerobic bioreactor cultures of strains IMS0522 and IMW088 on SMAGX, both completely ferment the [l]{.smallcaps}-arabinose in the medium. The strain lacking *PcaraT* (IMW088) did, however, exhibit a lower specific growth rate than strain IMS0522 (0.10 h^−1^ and 0.12h^−1^, respectively; Table [4](#tbl4){ref-type="table"}) and, consequently, required substantially more time for complete conversion of [l]{.smallcaps}-arabinose in the anaerobic batch cultures (Fig. [4](#fig4){ref-type="fig"}).

![Growth and extracellular metabolite concentrations in anaerobic cultures of the evolved [l]{.smallcaps}-arabinose consuming, glucose-phosphorylation negative *S. cerevisiae* strain IMS0522 and two derived strains with specific genetic modifications. Cultures were grown in bioreactors containing SM with 20 g L^−1^[l]{.smallcaps}-arabinose, 20 g L^−1^[d]{.smallcaps}-glucose and 20 g L^−1^[d]{.smallcaps}-xylose. (**a**) IMS0522, (**b**) IMW088 (*PcaraT*Δ), (**c**) IMW091 (Gal2^89I^ restored to Gal2^89T^). $\documentclass[12pt]{minimal}
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}{}$\diamondsuit$\end{document}$[d]{.smallcaps}-xylose. Data shown in the figure represent from a single growth experiment for each strain, data from independent replicate experiments are shown in Additional File 11. Derived biomass-specific conversion rates in the replicate experiments differed by less than 5%.](foy062fig4){#fig4}

###### 

Estimated copy numbers of the heterologously expressed *Lactobacillus plantarum* genes *araA*, *araB* and *araD* and *Penicillium chrysogenum PcaraT* in the evolved, anaerobically growing and glucose-tolerant 'arabinose specialist' strains *S. cerevisiae* IMS0520-IMS0523, obtained from two independent evolution experiments in SBRs (1 and 2), and in the parental strain IMX728. Copy numbers were estimated by comparing gene read depths to the average of all chromosomes.

                                                          *Reference*       *Reactor 1*   *Reactor 2*              
  ------------------------------------------------------- ----------------- ------------- ------------- ---------- ------
  *araA*                                                  17.5              8.7           19.3          19.5       16.4
  *araB*                                                  0.8               0.9           3.1           2.2        1.2
  *araD*                                                  0.9               1.0           1.2           1.0        1.1
  *PcaraT*                                                0.9               1.1           1.0           1.1        1.2
  *^[1](#tb3fn1){ref-type="fn"}^ Excluded chromosomes:*   *3, 10, 12, 16*   *2, 8, 12*    *12*          *12, 16*   

^1^Chromosomes excluded from the average read depth, based on duplication of chromosomal regions identified with the Magnolya algorithm (Nijkamp *et al.*[@bib31]).

###### 

Specific growth rates, biomass and product yields and carbon recoveries in anaerobic bioreactor batch cultures of *S. cerevisiae* strains IMS0522 ([d]{.smallcaps}-glucose-phosphorylation-negative strain evolved for [l]{.smallcaps}-arabinose fermentation in presence of [d]{.smallcaps}-xylose and [d]{.smallcaps}-glucose), IMW088 (IMS0522 with *PcaraTΔ*) and IMW091 (IMS0522 with Gal2^89I^ reverted to Gal2^89T^) in SM with 20 g L^−1^[l]{.smallcaps}-arabinose, 20 g L^−1^[d]{.smallcaps}-glucose and 20 g L^−1^[d]{.smallcaps}-xylose. The values are average and mean deviation of data from two independent cultures of each strain.

                            Yield (g g^−1^ L-arabinose consumed)   Carbon recovery                                   
  --------- --------------- -------------------------------------- ----------------- --------------- --------------- -------------
  IMS0522   0.121 ± 0.001   0.075 ± 0.002                          0.384 ± 0.004     0.090 ± 0.004   0.018 ± 0.001   96.9 ± 0.1
  IMW088    0.102 ± 0.01    0.079 ± 0.005                          0.381 ± 0.006     0.094 ± 0.002   0.019 ± 0.002   99.3 ± 2.1
  IMW091    0.069 ± 0.01    0.060 ± 0.005                          0.394 ± 0.004     0.088 ± 0.001   0.020 ± 0.001   103.4 ± 1.4

Amino acid substitutions in Gal2 at position N376 enable [l]{.smallcaps}-arabinose uptake in the presence of [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose {#sec3-4}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

A previous laboratory evolution study with [d]{.smallcaps}-xylose-fermenting, glucose-phosphorylation-deficient *S. cerevisiae* strains also identified mutations that led to a single-amino-acid change in Gal2 at position 376, which enabled growth on [d]{.smallcaps}-xylose in the presence of [d]{.smallcaps}-glucose (Farwick *et al.*[@bib14]). In the present study, the parental strain IMX728 could not only import [l]{.smallcaps}-arabinose via Gal2, but also via the fungal [l]{.smallcaps}-arabinose transporter *Pc*AraT, which is much less sensitive to glucose inhibition than Gal2 (Bracher *et al.*[@bib7]). To investigate whether the observed mutations in *GAL2* were also required for growth on [l]{.smallcaps}-arabinose in the presence of [d]{.smallcaps}-glucose in a strain background without *Pc*AraT, a short laboratory evolution experiment was conducted with the 'arabinose specialist' strain IMX660, which differed from strain IMX728 by the absence of *Pc*AraT. After approximately 100 h incubation in an aerobic shake flask on 20 g L^−1^[l]{.smallcaps}-arabinose and [d]{.smallcaps}-glucose, growth was observed and strain IMS0514 was obtained as a single colony isolate and confirmed to have a stable phenotype for growth on SMAG (data not shown). As in strains IMS0520-IMS0523, whole-genome sequencing of strain IMS0514 revealed a single mutation in *GAL2* at position 1128, in this case resulting in a Gal2^N376S^ substitution. Additionally, introduction of the Gal2^N376I^ substitution in both *GAL2* alleles of strain IMS0520 enabled immediate growth on SMAG of the arabinose specialist strain lacking *Pc*AraT (IMX1106, Fig. [5](#fig5){ref-type="fig"}).

![Growth of engineered glucose-phosphorylation-negative *S. cerevisiae* strains on [l]{.smallcaps}-arabinose in the presence and absence of [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose. An approximate set numbers of cells of strain *S. cerevisiae* IMX1106, expressing Gal2 with amino acid substitution N376 and parental strain IMX660 were plated on solid SM with [l]{.smallcaps}-arabinose (SMA), [l]{.smallcaps}-arabinose and [d]{.smallcaps}-glucose (SMAG) or [l]{.smallcaps}-arabinose, [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose (SMAGX). Plates were incubated aerobically at 30°C for 4 d.](foy062fig5){#fig5}

Sugar transport kinetics of Gal2 variants obtained by laboratory evolution {#sec3-5}
--------------------------------------------------------------------------

To examine inhibition by [d]{.smallcaps}-glucose of [l]{.smallcaps}-arabinose transport by different Gal2 variants found in evolved strains, the corresponding evolved *GAL2* alleles were expressed in *S. cerevisiae* DS68625. In this strain, which does not express the pathway required for arabinose metabolism, the hexose-transporter genes *HXT1* to *HXT7* and *GAL2* have been disrupted (Nijland *et al.*[@bib33]). To examine the extent to which [d]{.smallcaps}-glucose inhibited [l]{.smallcaps}-arabinose uptake by the different Gal2 variants, \[^14^C\]-[l]{.smallcaps}-arabinose-uptake experiments were performed at different concentrations of [d]{.smallcaps}-glucose (Fig. [6](#fig6){ref-type="fig"}). Consistent with earlier reports (Subtil and Boles [@bib43]; Farwick *et al.*[@bib14]), uptake of [l]{.smallcaps}-arabinose (50 mM) by wild-type Gal2 was inhibited by ca. 80% in the presence of 100 mM [d]{.smallcaps}-glucose (Fig. [6](#fig6){ref-type="fig"}). [d]{.smallcaps}-glucose inhibition was not significantly affected by the Gal2^T89I^ substitution but, under the same conditions, [l]{.smallcaps}-arabinose uptake by Gal2^N376I^, Gal2^N376S^ and Gal2^N376T^ was inhibited by only 20--30% (Fig. [6](#fig6){ref-type="fig"} and Additional File 12). The Gal2^N376I^, Gal2^N376S^ and Gal2^N376T^ substitutions yielded 25--60% lower K~m~ values for [l]{.smallcaps}-arabinose than wild-type Gal2, while their K~m~ values for [d]{.smallcaps}-glucose were one to two orders of magnitude higher than those of wild-type Gal2 (Table [5](#tbl5){ref-type="table"}). As a result, the ratios of the K~m~ values for [l]{.smallcaps}-arabinose vs. [d]{.smallcaps}-glucose was two orders of magnitude lower for the strains expression Gal2 variants with substitutions at position 376. For Gal2 variants that only carried an amino acid substitution at this position, transport capacities (V~max~) for [l]{.smallcaps}-arabinose and [d]{.smallcaps}-glucose differed by less than two-fold from those of wild-type Gal2 (Table [5](#tbl5){ref-type="table"}). These changes in transport kinetics are consistent with a strongly reduced competitive inhibition of [l]{.smallcaps}-arabinose transport by [d]{.smallcaps}-glucose.

![Effect of [d]{.smallcaps}-glucose on specific rates of L-arabinose uptake by different Gal2 variants. Uptake experiments were performed with 50 mM \[^14^C-\] [l]{.smallcaps}-arabinose in the presence of different [d]{.smallcaps}-glucose concentrations. Symbols indicate uptake rates observed with strain *S. cerevisiae* DS68625 expressing Gal2^N376T^ (○), Gal2^N376S^ (~•~), Gal2^N376I^ ($\documentclass[12pt]{minimal}
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###### 

K~m~ and V~max~ values for [l]{.smallcaps}-arabinose and [d]{.smallcaps}-glucose for Gal2 variants with amino acid substitutions at positions N376 and T89. Transport kinetics were measured by uptake studies with radioactive sugars after expression of *GAL2* alleles in *S. cerevisiae* DS68625. Values are average and mean deviation of two independent sets of uptake experiments. The detection limit for [d]{.smallcaps}-glucose uptake (V~max~) was 1.8 nmol^−1^ (mg biomass)^−1^ min^−1^. Data used to calculate K~m~ and V~max~ values are shown in Additional File 13.

                                          K~m~ (mM)   K~m~ ratio   V~max~ (nmol (mg biomass)^−1^ min^−1^)            
  --------------------------------------- ----------- ------------ ---------------------------------------- -------- ----------
  Gal2[**^1^**](#tb5fn1){ref-type="fn"}   335 ± 21    1.9 ± 0.2    176                                      75 ± 5   26 ± 1
  Gal2^N376I^                             117 ± 16    101 ± 47     1                                        39 ± 3   32 ± 18
  Gal2^N376S^                             186 ± 33    38 ± 1       5                                        64 ± 2   28 ± 1
  Gal2^N376T^                             171 ± 17    57 ± 1       3                                        65 ± 2   17 ± 4
  Gal2^T89I\ +\ N376T^                    103 ± 40    \-           \-                                       30 ± 2   \<1.8
  Gal2^T89I^                              99 ± 18     7 ± 0.2      15                                       22 ± 3   13 ± 0.1

^1^kinetic data for wild-type Gal2 were derived from Bracher *et al.* ([@bib7]).

A single Gal2^T89I^ substitution increased the K~m~ for [d]{.smallcaps}-glucose transport from 1.9 to 7 mM, while it decreased the K~m~ for [l]{.smallcaps}-arabinose from 335 to 99 mM. For both sugars, the Gal2^T89I^ substitution caused a 2--3 fold reduction of V~max~ (Table [5](#tbl5){ref-type="table"}). These kinetic properties suggest that Gal2^T89I^ may, by itself, confer a selective advantage at low extracellular [l]{.smallcaps}-arabinose concentrations. Remarkably, a Gal2 variant that harboured both the Gal2^N376T^ and Gal2^T89I^ substitutions no longer transported [d]{.smallcaps}-glucose, while K~m~ and V~max~ values for [l]{.smallcaps}-arabinose were similar to those of Gal2^T89I^ (Table [5](#tbl5){ref-type="table"}).

The Gal2^T89I^ substitution also occurs in a previously evolved pentose-fermenting strain {#sec3-6}
-----------------------------------------------------------------------------------------

Strain *S. cerevisiae* IMS0010 is an engineered pentose-fermenting strain that was previously evolved for improved anaerobic fermentation kinetics on mixtures of [d]{.smallcaps}-glucose, [d]{.smallcaps}-xylose and [l]{.smallcaps}-arabinose (Wisselink *et al.*[@bib64]). Sequence analysis of *GAL2* in IMS0010 showed that this strain contains the same Gal2^T89I^ substitution found in one of the two *GAL2* alleles in the independently evolved glucose-phosphorylation-negative strain IMS0522. Analysis of *GAL2* sequences in two intermediate strains in the construction and laboratory evolution of strain IMS0010 (strains IMS0002 and IMS0007; (Wisselink *et al.*[@bib64])) showed that this mutation was acquired during the evolution for improved kinetics of mixed-substrate utilization.

Reverting the Gal^T89I^ substitution negatively affects [l]{.smallcaps}-arabinose consumption {#sec3-7}
---------------------------------------------------------------------------------------------

CO~2~ production profiles of anaerobic bioreactor batch cultures (Additional File 8) indicated that strain IMS0522, in which one of the two *GAL2* alleles encodes both the Gal2^N376T^ and Gal2^T89I^ substitutions, grew faster on [l]{.smallcaps}-arabinose in the presence of [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose than strain IMS0523, in which both copies of *GAL2* only encode the Gal2^N376T^ substitution. To investigate whether the additional Gal2^T89I^ substitution contributed to this phenotype, the allele encoding this substitution was restored to 'Gal2^N376T^ only'. Anaerobic batch cultures of the resulting strain IMW091 on SMAGX showed a substantially reduced specific growth rate relative to its parental strain IMS0522 (0.069 h^−1^ and 0.12 h^−1^, respectively, Table [4](#tbl4){ref-type="table"}). As a consequence, the time needed to completely ferment [l]{.smallcaps}-arabinose in the presence of [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose was much shorter for the parental strain IMS0522 (Gal2^N376T^/Gal2^N376T\ T89I^) than for the strain IMW091 (Gal2^N376T^/Gal2^N376T\ T^); 25 and 45 h, respectively) (Fig. [4](#fig4){ref-type="fig"}).

DISCUSSION {#sec4}
==========

The *S. cerevisiae* strain used for this evolutionary engineering study combined genetic modifications that were previously shown to enable or stimulate growth on [l]{.smallcaps}-arabinose. Combined expression of a bacterial [l]{.smallcaps}-arabinose pathway (Sedlak and Ho [@bib40]; Becker and Boles [@bib4]; Wisselink *et al.*[@bib66]), overexpression of native non-oxidative pentose-phosphate-pathway enzymes (Kuyper *et al.*[@bib25]; Wisselink *et al.*[@bib66]), deletion of the non-specific aldose reductase gene *GRE3* (Träff *et al.*[@bib49]), deregulated expression of the Gal2 galactose/[l]{.smallcaps}-arabinose transporter (Tani *et al.*[@bib46]; Wang *et al.*[@bib61]), here accomplished by deletion of *GAL80* (Torchia *et al.*[@bib48]; Ostergaard *et al.*[@bib34]; Tani *et al.*[@bib46]) and expression of the fungal [l]{.smallcaps}-arabinose transporter *Pc*AraT (Bracher *et al.*[@bib7]) yielded a strain that, in aerobic shake-flask cultures, exhibited a specific growth rate on [l]{.smallcaps}-arabinose of 0.26 h^−1^. Moreover, deletion of all four genes encoding enzymes with glucose-phosphorylating activity rendered this 'arabinose-specialist' strain *S. cerevisiae* IMX728 unable to grow on glucose. Construction of this strain was completed within 3 months, which illustrates the power of Cas9-assisted genome editing combined with *in vivo* and *in vitro* DNA assembly methods (DiCarlo *et al.*[@bib11]; Kuijpers *et al.*[@bib24]; Mans *et al.*[@bib30]; Tsai *et al.*[@bib50]).

The specific growth rate of strain IMX728 on [l]{.smallcaps}-arabinose in aerobic batch cultures, which was achieved without evolutionary engineering or random mutagenesis, corresponded to 65% of the specific growth rate on glucose of the parental strain CEN.PK113--7D (Solis-Escalante *et al.*[@bib41]) and is the highest growth rate on [l]{.smallcaps}-arabinose hitherto reported for an engineered *S. cerevisiae* strain (Wisselink *et al.*[@bib66]; Wiedemann and Boles [@bib63]; Wang *et al.*[@bib60]). However, the genetic modifications in this strain did not enable anaerobic growth on [l]{.smallcaps}-arabinose. Anaerobic growth on [l]{.smallcaps}-arabinose requires that the biomass-specific [l]{.smallcaps}-arabinose consumption rate (q~arabinose~) is sufficiently high to meet the ATP requirement for cellular maintenance (ca. 1 mmol ATP (g biomass)^−1^ h^−1^, (Boender *et al.*[@bib6])). If [l]{.smallcaps}-arabinose uptake occurs via Gal2-mediated facilitated diffusion, anaerobic, fermentative metabolism of [l]{.smallcaps}-arabinose yields 1.67 ATP, while transport of [l]{.smallcaps}-arabinose exclusively via *Pc*AraT-mediated proton symport would result in a 60% lower ATP yield (Weusthuis *et al.*[@bib62]). Even if [l]{.smallcaps}-arabinose metabolism in the aerobic batch cultures of strain IMX728 would occur exclusively via the energetically much more favorable process of respiratory dissimilation (Bakker *et al.*[@bib3]; Verhoeven *et al.*[@bib57]), its specific growth rate of 0.26 h^−1^ would still correspond to a q~arabinose~ of at least 3 mmol g^−1^ h^−1^. This rate of [l]{.smallcaps}-arabinose metabolism should be sufficient to meet anaerobic maintenance requirements via fermentative metabolism. The inability of strain IMX728 to instantaneously grow on [l]{.smallcaps}-arabinose in anaerobic cultures therefore suggests that it cannot achieve the same q~arabinose~ under those conditions, which might reflect suboptimal expression, folding, membrane environment and/or stability of wild-type Gal2 in anaerobic cultures.

The observation that the two *GAL2* copies in individual strains evolved for anaerobic growth in [l]{.smallcaps}-arabinose in the presence of [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose encoded the same Gal^N376^ substitution, indicated that these substitutions most probably preceded gene duplication. The importance of these substitutions is further underlined by the observation that introduction of a single copy of the *GAL*^N376I^ allele enabled growth of an 'arabinose specialist' strain on [l]{.smallcaps}-arabinose in the presence of glucose and/or [l]{.smallcaps}-arabinose under aerobic conditions (Fig. [5](#fig5){ref-type="fig"}). *GAL* genes are transcriptionally regulated via pathways involving Mig1 and Gal80 (Ostergaard *et al.*[@bib34]). In the present study, Gal80-mediated repression was eliminated by deletion of its encoding gene. The observed growth of glucose-phosphorylation-negative strains expressing an evolved *GAL2^N376^* allele on [l]{.smallcaps}-arabinose in glucose-containing media indicates that any Mig1-mediated glucose repression of *GAL2* was incomplete. In the glucose-phosphorylation-negative strains, absence of Hxk2, which is involved in Mig1-dependent glucose repression (Ahuatzi *et al.*[@bib1]) is likely to have glucose derepression of *GAL* genes. Indeed, deletion of *HXK2* has been reported to stimulate co-consumption of glucose and galactose (Raamsdonk *et al.*[@bib36]). Additionally, in the same *S. cerevisiae* genetic background, combined deletion of *MIG1*, *GAL6* and *GAL80* was shown not to significantly affect *GAL2* transcript levels (Bro *et al.*[@bib8]).

Two previous studies used [d]{.smallcaps}-glucose-phosphorylation-negative [d]{.smallcaps}-xylose-fermenting strains to evolve for [d]{.smallcaps}-glucose tolerance of [d]{.smallcaps}-xylose utilization (Farwick *et al.*[@bib14]; Nijland *et al.*[@bib33]). These studies identified mutations in hexose transporters that reduced [d]{.smallcaps}-glucose sensitivity of [d]{.smallcaps}-xylose transport. In Gal2, which also transports [d]{.smallcaps}-xylose (Farwick *et al.*[@bib14]) and in a chimera of Hxt3 and Hxt6 (Hxt36) (Nijland *et al.*[@bib33]), these mutations caused amino acid substitutions at the corresponding positions N376 and N367, respectively. Using *in silico* models of the three-dimensional structure of Gal2 and Hxt36, based on the crystal structure of the *E. coli* XylE [d]{.smallcaps}-xylose/H^+^ symporter, changes of the amino acid at these positions were predicted to confine the space in the substrate binding pocket for the hydroxymethyl group of [d]{.smallcaps}-glucose (Sun *et al.*[@bib45]; Farwick *et al.*[@bib14]; Nijland *et al.*[@bib33]). Both studies showed that size, charge, polarity and presence of hydrophobic side chains for the substituted amino acid strongly influenced relative transport activities with [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose. The present study shows that modifications of Gal2 at this position also enable transport of [l]{.smallcaps}-arabinose in the presence of [d]{.smallcaps}-glucose. Of the Gal2^N376^ substitutions identified and kinetically analyzed in our study, Gal2^N376T^ showed the highest K~m~ and lowest V~max~ for [d]{.smallcaps}-glucose. Moreover, this substitution decreased the K~m~ for [l]{.smallcaps}-arabinose without affecting V~max~ for uptake of this pentose.

Of the four [d]{.smallcaps}-glucose-tolerant evolved strains isolated from the evolution experiments, strain IMS0522 showed significantly better [l]{.smallcaps}-arabinose fermentation performance than the other strains. Its [l]{.smallcaps}-arabinose consumption rate of 1.6 ± 0.08 g (g biomass)^−1^ h^−1^ and ethanol production rate of 0.61 ± 0.01 g (g biomass)^−1^ h^−1^ in anaerobic cultures are the highest reported to date for an engineered *S. cerevisiae* strain (Wisselink *et al.*[@bib66]; Wiedemann and Boles [@bib63]; Wang *et al.*[@bib60]). In addition to a Gal2^N376T^ substitution, one of the *GAL2* copies in this strain encoded an additional Gal2^T89I^ substitution, whose restoration to wild type resulted in a fermentation performance similar to that of the other strains. The physiological relevance of the mutation was further supported by its identification in a strain that was previously evolved for mixed-sugar fermentation (Wisselink *et al.*[@bib64]). By itself, the Gal2^T89I^ showed a reduced K~m~ for [l]{.smallcaps}-arabinose and an increased K~m~ for [d]{.smallcaps}-glucose, while the V~max~ for both sugars was decreased relative to that of wild-type Gal2. The Gal2^T89I^ variant was also investigated in a recent study that systematically investigated amino acid substitutions at positions within or close to the predicted [l]{.smallcaps}-arabinose binding pocket of Gal2 (Wang *et al.*[@bib61]). Subsequent expression of the Gal2^T89I^ substitution did not show a significant effect on the growth rate on [l]{.smallcaps}-arabinose (Wang *et al.*[@bib61]). However, our results suggest that, by itself, this substitution is advantageous for [l]{.smallcaps}-arabinose uptake in the presence of glucose and/or at low L-arabinose concentrations. Additionally, in the evolved strain IMS0010, in which Gal2 contained only this substitution, the mutations may have contributed to anaerobic co-consumption of [l]{.smallcaps}-arabinose and [d]{.smallcaps}-xylose (Wisselink *et al.*[@bib64]).

Transport assays with the Gal2^N376T,T89I^ variant showed complete loss of [d]{.smallcaps}-glucose transport capacity, combined with a reduced K~m~ and V~max~ for [l]{.smallcaps}-arabinose. In the context of the SBR protocol in which this variant evolved, these kinetic properties are particularly relevant during the growth phase in which the [l]{.smallcaps}-arabinose concentration declined, while [d]{.smallcaps}-glucose in still present at 20 g L^−1^. The complete loss of glucose transport activity of the Gal2^N376T,T89I^, which was encoded by only one of two copies of *GAL2* in the laboratory-evolved strain originating from a duplication of Chromosome XII, underline the importance of chromosomal CNV in laboratory evolution and neofunctionalization of duplicated genes (Gorter de Vries, Pronk and Daran [@bib10]). These results from a 500-generation laboratory evolution experiment illustrate how, during evolution in dynamic natural environments, similar duplication and neofunctionalization events, may have contributed to the diverse kinetic characteristics and substrate specificities of the Hxt transporter family in *S. cerevisiae* (Reifenberger, Boles and Ciriacy [@bib37]; Biswas *et al.*[@bib5]; Jordan *et al.*[@bib21]).

In addition to Gal2, the parental strain used in the evolution experiments expressed the fungal [l]{.smallcaps}-arabinose transporter *Pc*AraT, which upon expression in *S. cerevisiae* mediates high-affinity, [l]{.smallcaps}-arabinose-proton symport (K~m~ = 0.13 mM) and is much less sensitive to glucose inhibition than wild-type Gal2 (Bracher *et al.*[@bib7]). During the evolution experiments, no loss of function mutations was observed in *Pc*AraT. This observation indicates that its presence did not confer a strong selective disadvantage, for example as a result of the activity of a futile cycle caused by simultaneous facilitated diffusion and proton symport of [l]{.smallcaps}-arabinose. Moreover, the observations that deletion of *Pc*AraT resulted in decreased specific growth rate on [l]{.smallcaps}-arabinose and that presence of *Pc*AraT coincided with a faster consumption of [l]{.smallcaps}-arabinose towards the end of anaerobic batch cultures (Fig. [4b](#fig4){ref-type="fig"}), are in line with its reported low V~max~ and low K~m~ for [l]{.smallcaps}-arabinose upon expression in *S. cerevisiae* (Bracher *et al.*[@bib7]). These results demonstrate the potential of high-affinity [l]{.smallcaps}-arabinose transporters to efficiently convert low concentrations of [l]{.smallcaps}-arabinose towards the end of fermentation processes, thereby preventing prolonged 'tailing' of industrial fermentation processes.

CONCLUSIONS {#sec5}
===========

Laboratory evolution of engineered, [l]{.smallcaps}-arabinose-metabolizing and glucose-phosphorylation-negative *S. cerevisiae* yielded evolved strains that anaerobically fermented [l]{.smallcaps}-arabinose in the presence of [d]{.smallcaps}-glucose and [d]{.smallcaps}-xylose. Amino acid substitutions in Gal2 that affected the kinetics of [l]{.smallcaps}-arabinose and [d]{.smallcaps}-glucose transport played a key role in this evolution. The best performing evolved strain contained two different mutated alleles of *GAL2*, encoding Gal2 variants with distinct kinetic properties. This result demonstrates the importance of engineering 'transporter landscapes' for uptake of individual sugars, consisting of transporters with complementary kinetic and/or regulatory properties, for efficient sugar conversion in dynamic, mixed-sugar fermentation processes.

SUPPLEMENTARY DATA {#sec6}
==================

Supplementary data are available at FEMSYR online.
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